Phase II Study of Abemaciclib + Pembrolizumab in KRAS-Mutated, PD-L1+, Stage IV Chemonaïve Non–Small Cell Lung Cancer and in Pretreated Squamous Cell Lung Cancer.
Congress and symposium participations > Congress · 2016
Authors: Tuncay GÖKSEL
2016-2016, Phase II Study of Abemaciclib + Pembrolizumab in KRAS-Mutated, PD-L1+, Stage IV Chemonaïve Non–Small Cell Lung Cancer and in Pretreated Squamous Cell Lung Cancer., Congress, Attendee, Austria, Vienna